1-10 of 10
Subodh Verma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

755-P: GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular–Risk Individuals with Type 2 Diabetes

AISHWARYA KRISHNARAJ, BRADY PARK, EHAB BAKBAK, RAJ VERMA, ADRIAN QUAN, HWEE TEOH, DAVID A. HESS, SUBODH VERMA
Journal: Diabetes
Diabetes 2024;73(Supplement_1):755-P
https://doi.org/10.2337/db24-755-P
Published: 14 June 2024
View articletitled, 755-P: GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular–Risk Individuals with Type 2 Diabetes
Meeting Abstracts

784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial

NEDA RASOULI, ANDREI-MIRCEA CATARIG, YASEMIN HANSEN, KIM HOULIND, CHETHANA RAMESH, BERNHARD LUDVIK, JOAKIM NORDANSTIG, HARALD SOURIJ, SUBODH VERMA, MARC P. BONACA
Journal: Diabetes
Diabetes 2024;73(Supplement_1):784-P
https://doi.org/10.2337/db24-784-P
Published: 14 June 2024
View articletitled, 784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial
Meeting Abstracts

21-LB: Prevalence of Atherosclerotic Cardiovascular Diseases in Women with Type 2 Diabetes across the Middle East and Africa—Primary Gender Analysis of the PACT-MEA Study

FATHEYA ALAWADI, SAMIR H. ASSAAD-KHALIL, WAEL ALMAHMEED, NAJI ALAMUDDIN, HESSA ALKANDARI, JIHAD A. HADDAD, LISE LOTTE N. HUSEMOEN, LANDMAN LOMBARD, RAYAZ A. MALIK, EMEL MASHAKI CEYHAN, HANI M. SABBOUR, SAM SALEK, GOURAV YADAV, SUBODH VERMA
Journal: Diabetes
Diabetes 2023;72(Supplement_1):21-LB
https://doi.org/10.2337/db23-21-LB
Published: 20 June 2023
View articletitled, 21-LB: Prevalence of Atherosclerotic Cardiovascular Diseases in Women with Type 2 Diabetes across the Middle East and Africa—Primary Gender Analysis of the PACT-MEA Study
Meeting Abstracts

792-P: GLP-1 RA Therapy Increases Circulating Vascular Regenerative Cell Content and Decreases Inflammatory Burden in People with T2D

AISHWARYA KRISHNARAJ, BRADY PARK, EHAB BAKBAK, YI PAN, ADRIAN QUAN, HWEE TEOH, SUBODH VERMA, DAVID A. HESS
Journal: Diabetes
Diabetes 2023;72(Supplement_1):792-P
https://doi.org/10.2337/db23-792-P
Published: 20 June 2023
View articletitled, 792-P: GLP-1 RA Therapy Increases Circulating Vascular Regenerative Cell Content and Decreases Inflammatory Burden in People with T2D
Journal Articles

Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels

David A. Hess, Daniella C. Terenzi, Subodh Verma
Journal: Diabetes
Diabetes 2021;70(8):1620–1622
https://doi.org/10.2337/dbi21-0025
Published: 13 August 2021
View articletitled, Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels
Open the PDF for Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels in another window
Meeting Abstracts

80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

ROBERT F. KUSHNER, MELANIE J. DAVIES, JOHN DEANFIELD, W. TIMOTHY GARVEY, OLE JEPPESEN, USMAN KHALID, MIKHAIL N. KOSIBOROD, PETER N. LAURSEN, DOMENICA RUBINO, SUBODH VERMA
Journal: Diabetes
Diabetes 2021;70(Supplement_1):80-OR
https://doi.org/10.2337/db21-80-OR
Published: 01 June 2021
View articletitled, 80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis
Meeting Abstracts

82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET)

MARC EVANS, ABHISHEK SHANKAR CHANDRAMOULI, MADS FAURBY, KASPER S. MATTHIESSEN, PHILLIP BREDAHL MOGENSEN, SUBODH VERMA
Journal: Diabetes
Diabetes 2021;70(Supplement_1):82-LB
https://doi.org/10.2337/db21-82-LB
Published: 01 June 2021
View articletitled, 82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET)
Meeting Abstracts

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

MUTHIAH VADUGANATHAN, NAVEED SATTAR, DAVID H. FITCHETT, ANNE PERNILLE OFSTAD, MARTINA BRUECKMANN, JYOTHIS T. GEORGE, SUBODH VERMA, MICHAELA MATTHEUS, CHRISTOPH WANNER, SILVIO E. INZUCCHI, BERNARD ZINMAN, JAVED BUTLER
Journal: Diabetes
Diabetes 2020;69(Supplement_1):30-OR
https://doi.org/10.2337/db20-30-OR
Published: 01 June 2020
View articletitled, 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Meeting Abstracts

271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF

SILVIO E. INZUCCHI, KIERAN DOCHERTY, LARS KOBER, MIKHAIL N. KOSIBOROD, FELIPE MARTINEZ, PIOTR PONIKOWSKI, MARC S. SABATINE, SCOTT SOLOMON, JAN BELOHLAVEK, MICHAEL BÖHM, CHERN-EN CHIANG, RUDOLF A. DE BOER, MIRTA DIEZ, ANDREJ DUKAT, CHARLOTTA E.A. LJUNGMAN, SUBODH VERMA, DAVID L. DEMETS, OLOF BENGTSSON, ANNA MARIA LANGKILDE, MIKAELA SJÖSTRAND, PARDEEP JHUND, JOHN J. MCMURRAY
Journal: Diabetes
Diabetes 2020;69(Supplement_1):271-OR
https://doi.org/10.2337/db20-271-OR
Published: 01 June 2020
View articletitled, 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF
Meeting Abstracts

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

SUBODH VERMA, LAWRENCE A. LEITER, ABHINAV SHARMA, BERNARD ZINMAN, MICHAELA MATTHEUS, DAVID H. FITCHETT, JYOTHIS T. GEORGE, ANNE PERNILLE OFSTAD, CHRISTOPH WANNER, SILVIO E. INZUCCHI
Journal: Diabetes
Diabetes 2020;69(Supplement_1):28-OR
https://doi.org/10.2337/db20-28-OR
Published: 01 June 2020
View articletitled, 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME